The discovery
that type I interferon’s (IFNs) (IFN-α and IFN-β) have antitumor actions,
including promotion of innate and acquired antitumor immune
responses, suppression of proliferation and induction
of apoptosis of tumor cells.
In addition to
their well-known ability to inhibit virus replication, was initially welcomed
with great excitement.
Actually, type I
IFNs represent the cytokines exhibiting the longest record of use in the
treatment of certain hematological malignancies such as hairy cell leukemia and
chronic myeloid leukemia.
No comments:
Post a Comment